{"entity":{"id":"nct04689347","kind":"trial","name":"5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.","aka":[],"tldr":"A phase 1/2 trial of bevacizumab (glioblastoma use), fOLFIRI (5-FU, leucovorin, irinotecan), fOLFOX (5-FU, leucovorin, oxaliplatin) and temozolomide in colorectal cancer, run by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, now recruiting.","summary":"5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. is a phase 1/2, interventional study registered as NCT04689347 by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, with a registry enrolment figure of 27 participants, started 2021-01-01 and due to reach its primary completion in 2026-04-30. Interventions recorded: Bevacizumab; Irinotecan; Leucovorin; 5Fluorouracil; Temozolomide. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: (Phase 1b) safety and to determine the recommended phase 2 dose of the combination of FLIRT- bevacizumab in patients with MGMT silenced and MSS mCRC, previously untreated for advanced disease. (Phase 2) efficacy of FLIRT/bev. Colorectal eligibility wording from the registry: \"Histologically confirmed metastatic adenocarcinoma of the colon and/or rectum\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04689347","url":"https://clinicaltrials.gov/study/NCT04689347"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["bevacizumab-glioma","folfiri","folfox","temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04689347","phase":"1/2","setting":"Phase 1b/2 Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","enrolled":27,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04689347/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}